Appendix A: Decision paper considered by the Institute's Guidance Executive
History
Documents created during the development process.
Background information
-
-
Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 77 KB)
-
-
Appendix A: Review decision paper considered by the Institute’s Guidance Executive
-
Appendix A: Decision paper considered by the Institute's Guidance Executive (PDF 77 KB)
-
-
Appendix A: provisional matrix of consultees and commentators
-
Appendix A: provisional matrix of consultees and commentators (PDF 32 KB)
-
Appendix B: proposal paper presented to NICE's Guidance Executive
-
Appendix B: proposal paper presented to NICE's Guidance Executive (PDF 203 KB)
Leukaemia (lymphocytic) - fludarabine: Final appraisal determination
-
Leukaemia (lymphocytic) - fludarabine: Final appraisal determination information
-
Leukaemia (lymphocytic) - fludarabine: Final appraisal determination document
-
Leukaemia (lymphocytic) - fludarabine: Final appraisal determination document (PDF 78 KB)
-
Leukaemia (lymphocytic) - fludarabine: Final appraisal determination - Response to consultee and commentator comments and public and web comments
-
-
Leukaemia: Final appraisal determination - consultee and commentator comments
-
Leukaemia: FAD - consultee and commentator comments: Department of Health
-
Leukaemia: FAD - consultee and commentator comments: Department of Health (PDF 23 KB)
-
Leukaemia: FAD - consultee and commentator comments: Royal College of Pathologists
-
Leukaemia: FAD - consultee and commentator comments: Royal College of Pathologists (PDF 43 KB)
-
Leukaemia: FAD - consultee and commentator comments: Children with leukaemia
-
Leukaemia: FAD - consultee and commentator comments: Children with leukaemia (PDF 239 KB)
-
Leukaemia: FAD - consultee and commentator comments: Cancer backup
-
Leukaemia: FAD - consultee and commentator comments: Cancer backup (PDF 30 KB)
-
Leukaemia: FAD - consultee and commentator comments: British committee for standards in haematology
-
-
Leukaemia: FAD - consultee and commentator comments: Schering Health Care Ltd - MHRA update
-
-
Leukaemia: FAD - consultee and commentator comments: Schering Health Care Ltd
-
Leukaemia: FAD - consultee and commentator comments: Schering Health Care Ltd (PDF 38 KB)
-
Leukaemia: Final appraisal determination - expert comments
-
Leukaemia: FAD - expert comments: Dr Howard Pearce on the evaluation report
-
Leukaemia: FAD - expert comments: Dr Howard Pearce on the evaluation report (PDF 13 KB)
-
Leukaemia: FAD - expert comments: Dr Howard Pearce on the ACD
-
Leukaemia: FAD - expert comments: Dr Howard Pearce on the ACD (PDF 13 KB)
-
Leukaemia: FAD - expert comments: Dr Andrew Pettit
-
Leukaemia: FAD - expert comments: Dr Andrew Pettit (PDF 13 KB)
-
Leukaemia: FAD - expert comments: Professor Terry Hamblin
-
Leukaemia: FAD - expert comments: Professor Terry Hamblin (PDF 25 KB)
-
Leukaemia: FAD - expert comments: Jane Barnard
-
Leukaemia (lymphocytic) - fludarabine (appraisal consultation document)
Evidence considered
-
Evidence considered
-
Leukaemia (lymphocytic) - fludarabine: pre meeting briefing
-
Leukaemia (lymphocytic) - fludarabine: pre meeting briefing (PDF 74 KB)
-
Leukaemia (lymphocytic) - fludarabine: pre meeting briefing erratum
-
Leukaemia (lymphocytic) - fludarabine: pre meeting briefing erratum (PDF 18 KB)
-
Leukaemia (lymphocytic) - fludarabine: evidence review group report
-
Leukaemia (lymphocytic) - fludarabine: evidence review group report (PDF 673 KB)
-
Expert written personal statements
-
Pettitt
-
-
Pearce
-
-
Hamblin
-
-
Barnard
-
-
NICE clarification and responses
-
Schering Health Care Ltd - response 2
-
-
Schering Health Care Ltd - response
-
-
NICE Clarification letter
-
-
Manufacturer submission
-
Schering Health Care Ltd - Appendices
-
-
Schering Health Care Ltd - Submission
-